{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T22:39:58Z","timestamp":1648593598848},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1097\/rlu.0000000000001512","type":"journal-article","created":{"date-parts":[[2016,12,31]],"date-time":"2016-12-31T15:24:47Z","timestamp":1483197887000},"page":"191-192","source":"Crossref","is-referenced-by-count":1,"title":["18F-FDG PET\/CT in the Staging and Management of Breast Cancer"],"prefix":"10.1097","volume":"42","author":[{"given":"JR","family":"Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Bassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicens","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210204","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1007\/s13277-014-2495-7","article-title":"Glycolytic activity with 18F-FDG PET\/CT predicts final neoadjuvant chemotherapy response in breast cancer","volume":"35","author":"Garc\u00eda Vicente","year":"2014","journal-title":"Tumour Biol"},{"key":"R2-7-20210204","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s13193-015-0421-0","article-title":"Utility of [18F] fluorodeoxyglucose positron emission tomography\/computed tomography (FDG PET\/CT) in the initial staging and response assessment of locally advanced breast cancer patients receiving neoadjuvant chemotherapy","volume":"6","author":"Hulikal","year":"2015","journal-title":"Indian J Surg Oncol"},{"key":"R3-7-20210204","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.remn.2010.02.004","article-title":"[Diagnostic and therapeutic impact of 18F-FDG-PET\/CT in patients with suspected breast cancer recurrence]","volume":"29","author":"Palomar Mu\u00f1oz","year":"2010","journal-title":"Rev Esp Med Nucl"},{"key":"R4-7-20210204","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/2191-219X-2-61","article-title":"Quantitative hormone therapy follow-up in an ER+\/ER\u03b1KD mouse tumor model using FDG and [11C]-methionine PET imaging","volume":"2","author":"Paquette","year":"2012","journal-title":"EJNMMI Res"},{"key":"R5-7-20210204","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/jama.2009.1204","article-title":"Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study","volume":"302","author":"Ellis","year":"2009","journal-title":"JAMA"},{"key":"R6-7-20210204","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2191-219X-2-34","article-title":"Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients","volume":"2","author":"Kurland","year":"2012","journal-title":"EJNMMI Res"},{"key":"R7-7-20210204","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11523-014-0309-x","article-title":"Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET\/CT","volume":"9","author":"Boers-Sonderen","year":"2014","journal-title":"Target Oncol"},{"key":"R8-7-20210204","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cam4.102","article-title":"FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer","volume":"2","author":"Chen","year":"2013","journal-title":"Cancer Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000001512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:17:38Z","timestamp":1620973058000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201703000-00007"}},"subtitle":["Value in Disease Outcome and Planning Therapy"],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000001512","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}